Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Diabetes Mellitus, Insulin-Dependent, 12 2Uveal Melanoma 1Salivary Gland Neoplasms 1

Interventions

Ipilimumab 3Triamcinolone Acetonide 2Ranibizumab 2Nivolumab 2Amplified Fragment Length Polymorphism Analysis 2treosulfan 1salicylhydroxamic acid 1aldesleukin 1Ultrasonography 1Tramadol 1Temozolomide 1Tamoxifen 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Sorafenib 1Rose Bengal 1Radiosurgery 1Physical Examination 1Pharmacogenomic Testing 1Interviews as Topic 1Immunotherapy 1Ibuprofen 1Gemcitabine 1Eye Enucleation 1Cyclophosphamide 1Cisplatin 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Uveal Melanoma × CTLA-4 Antigen × Clear all
NCT03068624 2024-01-25

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

M.D. Anderson Cancer Center

Phase 1 Unknown
34 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡